LAS VEGAS, NV — October 16, 2025 — Leads & Copy — Odyssey Health, Inc. (OTCQB: ODYY) has announced it has signed a sub-licensing agreement for exclusive, worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities. The definitive agreement, managed through its subsidiary Odyssey Medical Devices, Inc., is subject to certain closing conditions.
The BreastCheck® test can be done at home and takes just 15 minutes, providing immediate results. It has been proven to be a reliable guide in the initial identification of potential breast abnormalities. While BreastCheck® is not a replacement for a mammogram, it is an effective first-line screening device. The technology is FDA registered in the United States, the European Union, and the United Kingdom.
Michael Redmond, CEO of Odyssey, stated that this is a major step forward and notes that early detection has significantly increased breast cancer survival rates in recent years. He notes that it is estimated that 317,000 new cases of invasive breast cancer will be diagnosed in women in the United States this year and that statistics show that 1 in 8 women in the United States will develop breast cancer in their lifetime. Mr. Redmond also notes that the breast cancer diagnostics market is a rapidly growing sector, currently valued in the low tens of billions of dollars depending on what is included, with forecasts to double, or more, over the next 8-10 years and is being driven by technological advances, such as imaging, AI, genomics, the rising incidence of breast cancer globally, greater emphasis on early detection, and expanding healthcare access especially in emerging markets.
Mr. Redmond also commented that they expect to begin commercialization and generate initial revenue from BreastCheck® in the near future, marking their transition from a development-stage to a revenue-generating medtech company.
BreastCheck®, a product of Davion Healthcare PLC, is a safe, accurate and low-cost, way to routinely monitor for breast abnormalities and is intended to be an adjunct to established procedures for the detection of breast disease, such as clinical breast examination and mammography. Abnormalities within the breast frequently produce additional breast heat. BreastCheck® averages temperature at three areas on each breast. By comparing the temperature of corresponding areas of one breast to the other and entering the results on the BreastCheck® Mobile App, results can be interpreted immediately.
Breast cancer is the most common cancer in women worldwide and a leading cause of cancer-related deaths. It occurs when abnormal cells in the breast grow uncontrollably, forming tumors that may spread to other parts of the body. The American Cancer Society estimates that in the United States about 316,950 invasive and 59,080 non-invasive cases are expected in 2025 and breast cancer accounts for roughly 30% of new cancers among women. According to the World Health Organization, in 2022, an estimated 2.3 million women were newly diagnosed with breast cancer worldwide and around 670,000 die from the disease. If current trends continue, by 2050 the number of new breast cancer cases per year is projected to rise to 3.2 million globally.
Odyssey Health, Inc. (OTCQB: ODYY) is a medical technology company with a focus in the area of life- saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity. Odyssey Medical Devices, Inc is a wholly owned subsidiary of Odyssey Health Inc.
Contact:
Rich Cockrell
877.889.1972
investorrelations@cg.capital
Source: Odyssey Health, Inc.
